Zhihui Wang

Shanghai Xihua Scientific Co. Ltd. was founded in the China Pilot (Shanghai) Free Trade Zone in February 2015. Xihua has become an international biomedical technology entity company, which matches the quality standards not only in China, but also in the United States. Shanghai Xihua has two locations in the Shanghai Zhang Jiang Pharm Valley. Currently, there are over 5,600 sq.m. of laboratory and office space, more than 240 employees in Shanghai, 31 sets of LC-MS, and more than 120 pieces of other equipment. In Princeton, New Jersey, Xihua has an affiliate Primera Analytical Solutions Corp., a CMC and bio-analytical services laboratory, which has been inspected by the US FDA many times. Primera has about 100 researchers. Xihua provides one-stop service for global pharmaceutical industry with high-quality and efficiency in late phase drug research and development, including innovative and generic drug CMC, API process development, formulation development, analytical testing, bio-analytical, clinical trial services and statistics. Xihua also has services in study and quality related consultation and training. Xihua has established wide partnerships with more than 100 clients, which consist of pharmaceutical companies, hospital clinical units, clinical CROs, universities and research institutes, and others.

益方生物科技（上海）有限公司是一家成立于2013年的创业型生物医药公司，致力于肿瘤，肿瘤免疫，代谢领域的新药研发，公司产品管线已包含肺癌、乳腺癌，肿瘤免疫和痛风等领域靶向治疗的小分子候选药物，同时公司也在积极开发其他肿瘤及免疫肿瘤靶点的药物。公司目前有四个自主研发的1类新药，分别在中、美两地进行临床一、二期试验。 益方的目标不仅是要让中国而且是要让全世界的患者从我们研发的新药中受益，与此同时，我们也在资本市场上获得认可（2017年获得奥博资本与礼来亚洲基金的投资），与他们的战略合作将为公司今后的方向打下坚实的基础，在未来的全球医药市场上获得快速发展。

GluBio Therapeutics is a pioneering TPD company dedicated to developing targeted protein degraders for human diseases with unmet medical needs. Founded by seasoned drug developers with deep knowledge and expertise in TPD drug discovery, the company has established a proprietary TPD discovery platform and robust screening capability. GluBio is advancing a diverse pipeline of highly selective small-molecule degraders across multiple therapeutic areas including oncology and immunology. The company has research operations in both San Diego, CA, USA and Shanghai, China.

Lilly Asia Ventures

Regor Therapeutics is a clinical stage company dedicated to the discovery and development of innovative and clinically differentiated medicines by leveraging the proprietary CARD (Computer Accelerated Rational Discovery) Platform. The company focuses mainly on three therapeutic areas, oncology, immunology, and metabolic disorders. By seamlessly integrating CARD with structural biology, computational chemistry, therapeutic biology, medicinal chemistry, and clinical development, Regor has successfully assembled a world-class scientific team and established a highly efficient new drug innovation engine to enable the discovery and development of best- and first-in-class molecules.

Shanghai Xihua Scientific Co. Ltd. was founded in the China Pilot (Shanghai) Free Trade Zone in February 2015. Xihua has become an international biomedical technology entity company, which matches the quality standards not only in China, but also in the United States. Shanghai Xihua has two locations in the Shanghai Zhang Jiang Pharm Valley. Currently, there are over 5,600 sq.m. of laboratory and office space, more than 240 employees in Shanghai, 31 sets of LC-MS, and more than 120 pieces of other equipment. In Princeton, New Jersey, Xihua has an affiliate Primera Analytical Solutions Corp., a CMC and bio-analytical services laboratory, which has been inspected by the US FDA many times. Primera has about 100 researchers. Xihua provides one-stop service for global pharmaceutical industry with high-quality and efficiency in late phase drug research and development, including innovative and generic drug CMC, API process development, formulation development, analytical testing, bio-analytical, clinical trial services and statistics. Xihua also has services in study and quality related consultation and training. Xihua has established wide partnerships with more than 100 clients, which consist of pharmaceutical companies, hospital clinical units, clinical CROs, universities and research institutes, and others.

益方生物科技（上海）有限公司是一家成立于2013年的创业型生物医药公司，致力于肿瘤，肿瘤免疫，代谢领域的新药研发，公司产品管线已包含肺癌、乳腺癌，肿瘤免疫和痛风等领域靶向治疗的小分子候选药物，同时公司也在积极开发其他肿瘤及免疫肿瘤靶点的药物。公司目前有四个自主研发的1类新药，分别在中、美两地进行临床一、二期试验。 益方的目标不仅是要让中国而且是要让全世界的患者从我们研发的新药中受益，与此同时，我们也在资本市场上获得认可（2017年获得奥博资本与礼来亚洲基金的投资），与他们的战略合作将为公司今后的方向打下坚实的基础，在未来的全球医药市场上获得快速发展。

GluBio Therapeutics is a pioneering TPD company dedicated to developing targeted protein degraders for human diseases with unmet medical needs. Founded by seasoned drug developers with deep knowledge and expertise in TPD drug discovery, the company has established a proprietary TPD discovery platform and robust screening capability. GluBio is advancing a diverse pipeline of highly selective small-molecule degraders across multiple therapeutic areas including oncology and immunology. The company has research operations in both San Diego, CA, USA and Shanghai, China.

Lilly Asia Ventures

Regor Therapeutics is a clinical stage company dedicated to the discovery and development of innovative and clinically differentiated medicines by leveraging the proprietary CARD (Computer Accelerated Rational Discovery) Platform. The company focuses mainly on three therapeutic areas, oncology, immunology, and metabolic disorders. By seamlessly integrating CARD with structural biology, computational chemistry, therapeutic biology, medicinal chemistry, and clinical development, Regor has successfully assembled a world-class scientific team and established a highly efficient new drug innovation engine to enable the discovery and development of best- and first-in-class molecules.